Valeant to acquire Dow Pharmaceuticals

US-based Valeant Pharmaceuticals International has agreed to acquire Dow Pharmaceutical Sciences, a privately held US dermatology company, for $285 million (£190 million)

Marc Barber

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses. More by Marc Barber

Valeant to acquire Dow Pharmaceuticals

Marc Barber

Related Stories

General Election 2024 – what do scale-ups want to see?

ThinCats to back high-growth companies with £300m fund

Fastest-growing companies in the UK revealed

Litestream Ventures unveils plans for ‘click-to-invest’ TV series

Related Topics